Complete disease clearance as a novel composite endpoint to predict long-term relapse in vedolizumab-treated patients with ulcerative colitis: A post-hoc analysis from the VIEWS randomised controlled trial

Category Primary study
ConferenceWorld Gastroenterology Organisation and Gastroenterological Society of Australia World Congress of Gastroenterology, Australian Gastroenterology Week 2025
Year 2025
This article has no abstract
Epistemonikos ID: ecd61c4243fa7c4b1760b22cf1f98d7a425142df
First added on: Nov 01, 2025